Redbird Research

The trials here

What the 13 trials at this site are about, from their registry records.

Conditions

• Depression7 trials
• Alzheimer disease2 trials
• Migraine2 trials
• Bipolar disorder1 trial
• Insomnia1 trial
• Schizophrenia1 trial

Phase

• Phase 310 trials
• Phase 23 trials

Status

• Recruiting7 trials
• Completed3 trials
• Active, not recruiting2 trials
• Enrolling by invitation1 trial

Lead sponsor

• Bristol-Myers Squibb2 trials
• LB Pharmaceuticals Inc.2 trials
• TriGemX Bio, Inc.2 trials
• Xenon Pharmaceuticals Inc.2 trials
• Cybin IRL Limited1 trial
• and 4 more

Running trials

• Recruiting

  A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

  NCT07674654· Phase 3· TriGemX Bio, Inc.· Source

  Contact: Annemarie Vance

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

  NCT07645924· Phase 3· TriGemX Bio, Inc.· Source

  Contact: Annemarie Vance

• Recruiting

  A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

  NCT07592689· Phase 3· Definium Therapeutics US, Inc.· Source

  Contact: Pam Pioquinto

• Recruiting

  52-week Open Label Safety-Tolerability Study

  NCT07369154· Phase 3· LB Pharmaceuticals Inc.· Source

  Contact: Pamela Pioquinto

• Recruiting

  Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

  NCT07494305· Phase 2· LB Pharmaceuticals Inc.· Source

  Contact: Haley Lefever

• Recruiting

  A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

  NCT06937229· Phase 3· Bristol-Myers Squibb· Source

  Contact: Jelena Kunovac, Site 1649

• Enrolling by invitation

  Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)

  NCT06605105· Phase 3· Cybin IRL Limited· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

  NCT07011732· Phase 3· Bristol-Myers Squibb· Source

  Contact: Jelena Kunovac, Site 1649

• Active, not recruiting

  An Open-Label Study of Azetukalner in Major Depressive Disorder

  NCT06922110· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Active, not recruiting

  A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

  NCT06775379· Phase 3· Xenon Pharmaceuticals Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Depression3 recruiting
• Alzheimer disease2 recruiting
• Migraine2 recruiting
• Bipolar disorder1 recruiting
• Schizophrenia1 recruiting

Closed trials

• Completed

  A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder

  NCT07193563· Phase 2· Engrail Therapeutics INC· Source

• Recruiting

  Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

  NCT06559306· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

  NCT06254612· Phase 2· Sirtsei Pharmaceuticals, Inc.· Source